The Valley Desk

NCT04317040 · Interventional trial

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

Overall registry status Completed

Phase 3

Conditions Coronavirus Disease 2019 (COVID-19)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov